ONCAlert | Upfront Therapy for mRCC

Gastric Cancer VIEW MORE >>

The FDA has granted Fast Track Designation to ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma, and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.